Summary
This study has compared the effect of repeated administration of charcoal and cholestyramine on the elimination of piroxicam.
Eight young adults were given piroxicam as a single dose of 20 mg, on 3 separate occasions. On one of the occasions charcoal was also given. On another occasion cholestyramine was also administered.
The mean elimination half-life after piroxicam alone was 53.1 h. This was reduced to 40.0 h by charcoal administration and to 29.6 h after administration of cholestyramine.
In the second phase of the study 7 elderly subjects received piroxicam 20 mg for 14 days on two occasions. Cholestyramine administration at the end of one of the periods reduced the mean elimination half-life of piroxicam from 52.3 h to 27.3 h.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Baciewicz AM, Isaacson ML, Lipscomb GL (1983) Cholestyramine resin in the treatment of digitoxin toxicity. Drug Intell Clin Pharm 17: 57–59
Guentert TM, Defoin R, Mosberg H (1988) The influence of cholestyramine on the elimination of tenoxicam and piroxicam. Eur J Clin Pharmacol 34: 283–289
Israili ZH, Dayton PG (1984) Enhancement of xenobiotic elimination: Role of intestinal excretion. Drug Metab Rev 15: 1123–1159
Karkkainen S, Neuvonen PJ (1985) Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics. Int J Clin Pharmacol Ther Toxicol 23: 219–225
Laufen H, Leitold M (1986) The effect of activated charcoal on the bioavailability of piroxicam in man. Int J Clin Pharmacol Ther Toxicol 24: 48–52
Levy G (1982) Gastrointestinal clearance of drugs with activated charcoal. N Engl J Med 307: 676–678
Neuvonen PJ (1982) Clinical pharmacokinetics of oral activated charcoal in acute intoxications. Clin Pharmacokinet 7: 465–489
Renowden S, Westmoreland D, White JP, Routledge PA (1985). Oral cholestyramine increased elimination of warfarin after overdose. Br Med J 291: 513–514
Rogers HJ, Spector RG, Morrison PJ, Bradbrook ID (1981) Comparative steady-state pharmacokinetic study of piroxicam and flurbiprofen in normal subjects. Eur J Rheumatol Inflamm 4: 303–308
Tilstone WJ, Lawson DH, Omara F, Cunningham F (1981) The steady-state pharmacokinetics of piroxicam: effect of food and iron. Eur J Rheumatol Inflamm 4: 309–313
Twomey TM, Bartolucci SR, Hobbs DC (1980) Analysis of piroxicam in plasma by high-performance liquid chromatography. J Chromatogr 183: 104–108
Verbeeck RK, Richardson CJ, Blocka LN (1986) Clinical pharmacokinetics of piroxicam. J Rheumatol 13: 789–796
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ferry, D.G., Gazeley, L.R., Busby, W.J. et al. Enhanced elimination of piroxicam by administration of activated charcoal or cholestyramine. Eur J Clin Pharmacol 39, 599–601 (1990). https://doi.org/10.1007/BF00316105
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00316105